EMISPHERE TECHNOLOGIES, INC. (OTCMKTS:EMIS) Files An 8-K Results of Operations and Financial Condition
Item2.02 Results of Operations and Financial
Condition.
On March29, 2017, Emisphere Technologies, Inc. issued a press
release announcing results of operations for the fourth quarter
and year ended December31, 2016. A copy of the press release is
furnished herewith and is incorporated by reference herein as
Exhibit99.1.
Item9.01 Financial Statements and
Exhibits.
|
Exhibit No. |
Description |
|
| 99.1 |
Press Release of Emisphere Technologies, Inc., dated March29, 2017 |
About EMISPHERE TECHNOLOGIES, INC. (OTCMKTS:EMIS)
Emisphere Technologies, Inc. is a commercial-stage pharmaceutical and drug delivery company. The Company, in partnership with pharmaceutical companies, develops new formulations of existing products, as well as new chemical entities, using its Eligen Technology. Its first prescription medical food product is oral Eligen B12. The Company utilizes its Eligen Technology to create new oral formulations of therapeutic agents. Its product pipeline includes prescription drug and medical food product candidates that are being developed in partnership or internally. Its preclinical programs focus on the development of oral formulations of potentially new treatments for diabetes and products in the areas of cardiovascular, appetite suppression and pain and on the development and potential expansion of nutritional supplement products. The Eligen Technology is an applicable oral drug delivery technology based on the use of synthetic chemical compounds known as Eligen delivery agents, or carriers. EMISPHERE TECHNOLOGIES, INC. (OTCMKTS:EMIS) Recent Trading Information
EMISPHERE TECHNOLOGIES, INC. (OTCMKTS:EMIS) closed its last trading session 00.000 at 0.495 with shares trading hands.
